An in vivo CRISPR gene editing therapy receives standard FDA approval before 2028.

Question

Six frontier AI models put this at 20% by 27 Oct 2029. Full reasoning from every model.

WillHappen.ai · Accepted Answer

20% — the median of 6 frontier models, resolving by 2029-10-27.

Answer

Gemini (Google): 18% — Clinical trial timelines for lead candidates NTLA-2002 and NTLA-2001 make standard FDA approval before end-2027 nearly impossible. Intellia's Phase 3 HAELO trial readouts and BLA filing cannot comfortably occur with enough time for standard 10-month FDA review before 2028. Accelerated approval is more probable than full standard approval for initial rare disease indications, excluding it from this resolution. A surprise priority review designation with an unusually compressed review clock following early interim Phase 3 efficacy is the sole viable path.

Answer

Claude (Anthropic): 28% — Hinges on whether NTLA-2001/6240 (transthyretin amyloidosis) or a similar lead in vivo program completes Phase 3 and files in time. Intellia's NTLA-2001 and verve/other in vivo candidates are the furthest along, with pivotal trials reading out 2026-2027, leaving a narrow but plausible window for… Only ex vivo CRISPR therapies (Casgevy) have reached approval so far; in vivo editing has no precedent yet, so base rate for a first-in-class approval within a ~3 year… Biologics review typically takes 10-12 months after BLA filing, so a 2027 pivotal readout could plausibly yield approval by 2028-2029 if data are strong and no major…

Answer

GPT (OpenAI): 72% — The outcome mainly depends on whether a late-stage in vivo program delivers durable benefit with manageable safety in 2027–28. FDA already approved ex vivo CRISPR Casgevy in 2023, but no in vivo editor has yet cleared the efficacy and long-term safety bar. Intellia’s NTLA-2001 and other liver-directed programs have human proof of concept; a successful pivotal readout could support a 2028–29 BLA. Below-base risks are delayed pivotal enrollment, off-target or liver-safety signals, and FDA demands for longer follow-up; an accepted BLA by 2028 would raise odds…

Answer

Grok (xAI): 18% — Intellia NTLA-2001 MAGNITUDE readout-to-BLA clock vs end-2027. Phase 3 ATTR-CM trial, started 2024, is still enrolling; primary data expected no earlier than mid-2027. Even with priority review a BLA filed late 2027 cannot yield standard approval before 1 Jan 2028. No other in-vivo CRISPR (Verve-102, Beam, Editas) has entered pivotal studies, matching historic 12–24 mo lag of first gene-editor approvals.

Answer

DeepSeek (DeepSeek): 22% — It turns on whether Intellia's lonvo-z or a rival in vivo editor clears a full Phase 3 readout and FDA review within roughly two years. No in vivo CRISPR therapy has ever been approved; the only approved CRISPR drug, Casgevy, is ex vivo, so the base rate for this exact event is zero. Intellia's lonvo-z (NTLA-2002) is in Phase 3 for hereditary angioedema, with data expected around 2026-2027 and a filing possibly in 2027, leaving little margin before… The FDA has shown willingness to move fast on gene editing (Casgevy approved in 2023), but in vivo delivery, off-target editing, and long-term safety data remain the…

Answer

Qwen (Alibaba): 17% — Hinges on whether Intellia's NTLA-2001 Phase 3 data lands and clears FDA review within ~14 months. Intellia/Regeneron's NTLA-2001 (ATTR amyloidosis) is the furthest along in vivo CRISPR candidate, but Phase 3 MAGNITUDE data likely read out no earlier than mid-2026… Standard (not accelerated) approval requires demonstrated clinical benefit on a functional endpoint, which raises the evidentiary bar and makes FDA requesting additional… No other in vivo CRISPR program (Verve VERVE-101, Editas) is close enough to serve as a backup path; a single program's delay or safety signal collapses the probability…

An in vivo CRISPR gene editing therapy receives standard FDA approval before 2028.

A clinical trial begins testing a vascularized, 3D-bioprinted human organ in patients before 2032.

A fully lab-grown solid human organ is successfully transplanted into a patient before 2035.

Standard clinical turnaround for an ex vivo autologous gene editing therapy falls below 14 days before 2030.

Human germline gene editing results in a live birth before 2030.